EGFR and prostate cancer: However, the current anti-CTLA-4 agent showed no effect in a clinical study of prostate cancer [8], and anti-PD1 therapy showed less effect in colorectal cancer [9] and even promoted tumor progression for some patients with murine double minute2 (MDM2) amplification or epidermal growth factor receptor (EGFR) aberration [10].